TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
3.760
-0.060 (-1.57%)
At close: Dec 20, 2024, 4:00 PM
3.830
+0.070 (1.86%)
After-hours: Dec 20, 2024, 7:00 PM EST
TransCode Therapeutics Employees
TransCode Therapeutics had 10 employees as of December 31, 2023. The number of employees decreased by 9 or -47.37% compared to the previous year.
Employees
10
Change (1Y)
-9
Growth (1Y)
-47.37%
Revenue / Employee
n/a
Profits / Employee
-$1,492,656
Market Cap
1.97M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 10 | -9 | -47.37% |
| Dec 31, 2022 | 19 | 10 | 111.11% |
| Dec 31, 2021 | 9 | 3 | 50.00% |
| Dec 31, 2020 | 6 | 0 | - |
| Dec 31, 2019 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| cbdMD | 52 |
| Helius Medical Technologies | 22 |
| Cyclacel Pharmaceuticals | 12 |
| Bluejay Diagnostics | 10 |
| Phio Pharmaceuticals | 9 |
| Tivic Health Systems | 9 |
| Dermata Therapeutics | 8 |
| IMAC Holdings | 4 |
RNAZ News
- 3 days ago - TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial - PRNewsWire
- 21 days ago - TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split - GlobeNewsWire
- 24 days ago - TransCode Therapeutics, Inc. Announces $8 Million Private Placement - GlobeNewsWire
- 6 weeks ago - TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance - GlobeNewsWire
- 3 months ago - TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate - GlobeNewsWire
- 3 months ago - TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate - GlobeNewsWire
- 5 months ago - TransCode Therapeutics, Inc. Announces Closing of Public Offering - GlobeNewsWire
- 5 months ago - TransCode Therapeutics, Inc. Announces Pricing of Public Offering - GlobeNewsWire